MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Published:2019-09 Issue:9 Volume:14 Page:1666-1671
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Guo Robin^ORCID,Berry Lynne D.,Aisner Dara L.,Sheren Jamie,Boyle Theresa,Bunn Paul A.,Johnson Bruce E.,Kwiatkowski David J.,Drilon Alexander,Sholl Lynette M.,Kris Mark G.

Funder

Novartis

AADi

Revolution Medicines

Genentech

Roche

PharmaMar

AstraZeneca

Pfizer

Regeneron

IBM

National Cancer Institute

National Institutes of Health

Lung Cancer Research Foundation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer;Wu;J Clin Oncol,2018

2. Targeting MET in lung cancer: will expectations finally be MET?;Drilon;J Thorac Oncol,2017

3. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial [abstract];Camidge;J Clin Oncol,2018

4. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable;Reungwetwattana;Lung Cancer,2017

5. Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: phase II trial [abstract];Felip;J Clin Oncol,2018

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation;Thoracic Cancer;2024-09-10

2. Savolitinib in NSCLC: progress in the MET exon 14 journey;The Lancet Respiratory Medicine;2024-09

3. Analysis of miRNAs involved in mouse brain injury upon Coxsackievirus A6 infection;Frontiers in Cellular and Infection Microbiology;2024-08-22

4. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-Small Cell Lung Cancer—The INOLUNG Study;Cancers;2024-08-21

5. Prognostic Significance of EGFR, HER2, and c-Met Overexpression in Surgically Treated Patients with Adenocarcinoma of the Ampulla of Vater;Cancers;2024-08-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3